|Product Candidate / PROGRAM||Drug substance||Indication||Discovery||Pre-clinical||Phase 1||Phase 2||Phase 3/ Pivotal||EMA/FDA review||Commercial Rights|
|ERYZYME||Therapeutic enzymes||Metabolic diseases|
ERYZYME is a development program utilizing the ERYCAPS platform for enzyme-based therapies for rare and highly specialized conditions.
We believe that the encapsulation of the therapeutic enzymes in the red blood cells may be able to reduce the potential for allergic reactions and to allow the therapeutic substance to remain in the body longer as compared to non-encapsulated enzymes.
Different preclinical proof-of-principle studies are ongoing.